Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Opus Genetics, Inc. (IRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/27/2025: IRD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.58% | Avg. Invested days 14 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.67M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 159358 | Beta 0.24 | 52 Weeks Range 0.65 - 2.18 | Updated Date 05/17/2025 |
52 Weeks Range 0.65 - 2.18 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date 2025-05-08 | When Before Market | Estimate - | Actual -1.1128 |
Profitability
Profit Margin - | Operating Margin (TTM) -207.11% |
Management Effectiveness
Return on Assets (TTM) -38.95% | Return on Equity (TTM) -64.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -962644 | Price to Sales(TTM) 4.26 |
Enterprise Value -962644 | Price to Sales(TTM) 4.26 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA -2.55 | Shares Outstanding 31568500 | Shares Floating 27724682 |
Shares Outstanding 31568500 | Shares Floating 27724682 | ||
Percent Insiders 16.15 | Percent Institutions 16.63 |
Analyst Ratings
Rating 4.67 | Target Price 10.5 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Opus Genetics, Inc.
Company Overview
History and Background
Opus Genetics is a gene therapy company focused on developing treatments for inherited retinal diseases. Founded in 2020 as a spin-out from the University of Pennsylvania and Childrenu2019s Hospital of Philadelphia (CHOP), it aims to address unmet needs in inherited retinal disease (IRD) therapy development.
Core Business Areas
- Gene Therapy Development: Focuses on developing gene therapy candidates for specific IRDs, leveraging AAV vectors to deliver functional genes to retinal cells.
- Platform Technology: Utilizes a proprietary AAV platform optimized for retinal delivery and expression.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of gene therapy candidates in patients with IRDs.
Leadership and Structure
Opus Genetics has a management team with experience in gene therapy, ophthalmology, and drug development. The company structure is based on functional departments supporting research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- OPI-005 (RHO-linked autosomal dominant retinitis pigmentosa (adRP)): Gene therapy candidate for RHO-linked adRP. Market share data is unavailable as it is still in development. Competitors include companies developing gene therapies for inherited retinal diseases.
- OPI-004 (Leber congenital amaurosis (LCA)): Gene therapy candidate for LCA. Market share data is unavailable as it is still in development. Competitors include companies developing gene therapies for inherited retinal diseases.
Market Dynamics
Industry Overview
The gene therapy market for inherited retinal diseases is growing, driven by advancements in gene editing and delivery technologies and the high unmet need for effective treatments.
Positioning
Opus Genetics is positioned as a specialist in inherited retinal disease gene therapy, focusing on developing targeted therapies for specific genetic mutations.
Total Addressable Market (TAM)
The global inherited retinal disease market is estimated to be in the billions of dollars. Opus Genetics is targeting specific genetic subtypes within this broader market.
Upturn SWOT Analysis
Strengths
- Specialized focus on inherited retinal diseases
- Proprietary AAV vector platform
- Experienced management team
- Strong scientific foundation (spin-out from UPenn/CHOP)
Weaknesses
- Early-stage company with limited revenue
- High R&D expenses
- Dependence on clinical trial success
- Limited commercial infrastructure
Opportunities
- Potential to address unmet needs in IRDs
- Expanding gene therapy market
- Strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline to additional IRD targets
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Manufacturing challenges
Competitors and Market Share
Key Competitors
- SPRK
- EDIT
- CRSP
Competitive Landscape
Opus Genetics competes with both established pharmaceutical companies and smaller biotech firms in the gene therapy space. Its competitive advantage lies in its specialized focus on inherited retinal diseases and proprietary AAV platform.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available.
Future Projections: Future projections are not publicly available, but the company's success hinges on clinical trial progress and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing gene therapy candidates through clinical trials and expanding its research and development efforts.
Summary
Opus Genetics is a promising gene therapy company focused on inherited retinal diseases. It has a strong scientific foundation and a specialized AAV platform. However, it is an early-stage company with high R&D expenses and dependence on clinical trial success and needs to be aware of larger competitors in the market.
Similar Companies
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Industry reports
Disclaimers:
This analysis is based on publicly available information and limited by the company's private status. Market share data is estimated and may not be precise. Investment decisions should be based on independent research and professional advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Opus Genetics, Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2005-05-23 | CEO & Director Mr. George Magrath M.B.A., M.D., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://opusgtx.com |
Full time employees 18 | Website https://opusgtx.com | ||
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
